Functional and pharmacological studies would likewise be beneficial to test whether FGFR1 N546K and the FGFR1 ITD we observed in one additional patient represent valid targets for kinase inhibition in neuroblastoma patients. The gene discussed is FGFR1; the disease is neuroblastoma.